Six Investment Lessons, Explained Through Cars
After nearly two decades managing healthcare equity portfolios, I've noticed the best investments and the best cars have a remarkable amount in common.
I spend most of my professional life thinking about pharmaceutical pipelines, clinical trial endpoints, and healthcare regulatory environments. But I also spend a meaningful amount of time around extraordinary automobiles — most recently at the Scarsdale Concours D'Elegance, a show that has raised over $750,000 for Westchester County charities and draws some of the most remarkable vehicles in the world to our corner of New York.
Somewhere between studying a 1960s Ferrari and reviewing a biotech's Phase III data, it struck me: the language of cars and the language of investing are nearly identical. We talk about fundamentals, long-term value, timing the market, and knowing when to hold. We also talk about the ones that looked great on paper and fell apart the moment you drove them off the lot.
Here, then, is nearly two decades of market experience — translated entirely into automobiles.
Everyone was talking about it. Enormous hype, real media attention, and ultimately no one actually wanted to own one long-term. Sound familiar?
Never the flashiest option in the room. Never cheap. Refined continuously over decades. Always worth holding. The investors who bought early and stayed patient look very smart today.
Breathtaking to watch perform. The running costs, however, will quietly destroy you. There is always a cost to maintaining something that was never designed for real-world conditions.
Looked completely hopeless for years. Then the right leadership arrived and changed everything. Management matters more than the headlines ever suggest.
Conceived around a bold vision of the future. Beautifully differentiated. The idea was not wrong — the timing was. In markets as in engineering, vision without execution is just a concept car.
Boring? Absolutely. Appreciating asset with decades of proven reliability and a waiting list? Also yes. The fundamentals never stopped working — people just stopped paying attention to them.
Healthcare investing demands exactly this kind of discipline. Drug development timelines are long. Regulatory outcomes are uncertain. The gap between a promising Phase II result and a commercial product can span years. Investors who treat that process like a day trade consistently underperform those who trust their research, understand what they own, and give the thesis time to play out.
At Exome Asset Management, this is the philosophy we bring to every position in our portfolio. Rigorous fundamental research. Long-term perspective. No confusing noise for signal.
It is also, for what it is worth, the philosophy I bring to cars. You do not find a remarkable vintage automobile at the Scarsdale Concours because someone flipped it fast. You find it because someone recognized value, cared for it properly, and had the patience to let time do its work.
No one has ever handed a trophy to the guy who sold in six months.
Alex Forschner is the President of Exome Asset Management LLC, a healthcare-focused public equity investment firm. He is a board member of the Scarsdale Concours D'Elegance and has over 19 years of experience in global public and private equity markets.
Add comment
Comments